Janus Henderson Group PLC increased its stake in Immunocore to 257,080 shares valued at $16.7 million, while BNP PARIBAS ASSET MANAGEMENT raised its holdings by 16.2% to 397,463 shares worth $13.5 million. Institutional investors own 84.5% of the stock. UBS Group initiated coverage with a "sell" rating and a $24 price target, indicating a potential downside, while other analysts maintain a "Moderate Buy" rating with a consensus target price of $75.17. Immunocore reported a revenue increase of 26.2% year-over-year, with a quarterly earnings per share of ($0.23), surpassing expectations.
Major ETF providers, including BlackRock and Amundi, are competing for a share of the anticipated $5 billion to $10 billion influx into Indian bonds, following JPMorgan's inclusion of Indian debt in its emerging-market index. This move is expected to significantly boost investment in the sector.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
